• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
160085 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
1 y) S0 \, U2 M/ L7 H  C* n8 I, N7 ]5 m- F3 |2 f' e4 O4 U# _& S

+ J6 m; y: W8 E7 k  W' b9 I+ @Sub-category:
1 s' M# ]: G6 F1 J  D7 R6 cMolecular Targets , c" G* t0 }& }

9 j' x3 u* L% ~' ?
, u- P% A. L6 O: t  VCategory:' S0 i* Y4 s- _+ b- p& X6 R' S
Tumor Biology
3 ^+ K3 Q: |) t7 E$ |) m# Q5 ~# f. j) g' u0 G' K' _% s
& u) `" ], a. a: K
Meeting:
7 A9 e6 E/ d  Y+ w2011 ASCO Annual Meeting
. _; P* U( S' Y* ]' E% D8 {
' |4 [$ b* o7 S) f7 R' J+ v$ T) M( j& e/ u
Session Type and Session Title:+ c0 P9 x% [9 y& K2 M4 Q/ z
Poster Discussion Session, Tumor Biology   C% i4 s5 d# j# T5 T  M
& B+ h* B" V6 C& q5 U
* c" w  p3 T$ I. e) P7 X7 @
Abstract No:
9 O9 g1 l( I8 J# |: M10517
. b+ y5 v) X6 J- ^( R8 ^
& A( M: {$ ?: A8 l5 p" E( v$ O: c+ d6 `2 V4 j
Citation:
* O# A0 q: L2 O' u% Z- fJ Clin Oncol 29: 2011 (suppl; abstr 10517) - ]2 g: J3 b- Q5 P  `# I5 y; ~

6 f. p; }, y9 [$ Y9 \* u) Q9 P. r: L; \# ?
Author(s):
$ g* a: R2 M) n7 U5 {& E4 `0 hJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
4 I0 a' @9 P- G! q
9 s0 G6 b. j% p$ l/ l3 y4 b, C
/ g8 e3 A( F$ e) i, n
/ i+ \8 x/ A# ^4 eAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
. M3 P' s3 ~4 j0 y3 _/ W. `
0 N- P3 S( s9 P( jAbstract Disclosures
/ h9 m: ?) h% x$ O9 ^* u6 z) v+ T) X( ~
Abstract:
4 r7 b8 D7 G0 G) o/ e7 I6 }( s) \; q8 Y% p; J) K/ |% C
6 u5 M2 d$ y( w* X0 d4 @
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 P5 r9 j3 V+ j/ G# x
2 L* i& R: |! z 8 p- b! i- ?: V' ?' m; g
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
7 {( Z1 b+ S: E' i没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
. x2 I; i$ D. u+ n6 r
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 6 L. R' p( p& z" P3 G0 W8 t: r) D
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
: n$ j. M( u1 _7 }; qALK一个指标医院要900多 ...

: \1 T0 G# I- P  r2 X: k平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
. e9 |; @( ^4 _7 C3 W, B% u6 l. }- x( L  M: p- x; |  X4 o2 b
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表